jRCT2051260020招募中不适用
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
未提供0 个研究点目标入组 30 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Has histologically documented locally advanced/metastatic urothelial cancer. Locally advanced disease must not be amenable to resection or radiation with curative intent per investigator assessment
- •Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the investigator
- •Has received treatment with anti-programmed cell death [ligand] 1 (anti-PD-[L]1) therapy, platinum-based chemotherapy, and enfortumab vedotin (EV)
- •Prior therapy with disitamab vedotin (DV) is allowed but will not meet the requirement for prior treatment with EV, except in China, where participants may have received DV instead of EV before study entry
- •Has received a maximum of 3 prior lines of therapy
- •Has experienced radiographic disease progression on or after the immediate prior line of therapy before study entry
- •Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
- •Is eligible to receive at least one of the control arm nonplatinum chemotherapy options (paclitaxel, docetaxel, or vinflunine)
- •Is able to provide archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated
- •If human immunodeficiency virus (HIV) positive, has well-controlled HIV on antiretroviral therapy (ART)
- •If hepatitis B surface antigen (HBsAg) positive, has received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and has undetectable HBV viral load
- •If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load
- •Has adequate organ function
排除标准
- •Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- •Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- •HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- •Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade <= 1 or baseline from adverse event (AE) associated with anticancer therapy
- •Has received prior therapy with trophoblast cell-surface antigen 2 (TROP2)-targeted antibody drug conjugate (ADC)
- •Has received prior therapy with a topoisomerase 1 inhibitor-containing ADC
- •Has completed prior external radiotherapy within 6 weeks or stereotactic radiotherapy within 4 weeks of start of study intervention, or has radiation related toxicities, requiring corticosteroids
- •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
- •Has received prior chemotherapy for urothelial cancer with any of the study therapies in the control arm (paclitaxel, docetaxel, and vinflunine)
- •Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- •Has a current or past history of central nervous system (CNS) metastases and/or carcinomatous meningitis
- •Has an active infection requiring systemic therapy other than those permitted per protocol
- •Has a history of stem cell/solid organ transplant
- •Has not adequately recovered from major surgery, or has ongoing surgical complications
研究者
相似试验
招募中
3 期
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and ImmunotherapyRecurrent or Persistent Endometrial Cancer2024-511957-23-00Gilead Sciences Inc.179
招募中
3 期
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received Endocrine Therapy2022-502593-17-00Gilead Sciences Inc.428
招募中
2 期
Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast CancerBreast CancerNCT07371208Shanghai Jiao Tong University School of Medicine40
招募中
3 期
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Bladder CancerNCT07419295Merck Sharp & Dohme LLC590
招募中
3 期
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022)2023-508015-23-00Merck Sharp & Dohme LLC5